Article ; Online: Zinc Oxide Nanoparticles and Cancer Chemotherapy: Helpful Tools for Enhancing Chemo-sensitivity and Reducing Side Effects?
Biological trace element research
2023 Volume 202, Issue 5, Page(s) 1878–1900
Abstract: Cancer chemotherapy is still a serious challenge. Chemo-resistance and destructive side effects of chemotherapy drugs are the most critical limitations of chemotherapy. Chemo-resistance is the leading cause of chemotherapy failure. Chemo-resistance, ... ...
Abstract | Cancer chemotherapy is still a serious challenge. Chemo-resistance and destructive side effects of chemotherapy drugs are the most critical limitations of chemotherapy. Chemo-resistance is the leading cause of chemotherapy failure. Chemo-resistance, which refers to the resistance of cancer cells to the anticancer effects of chemotherapy drugs, is caused by various reasons. Among the most important of these reasons is the increase in the efflux of chemotherapy drugs due to the rise in the expression and activity of ABC transporters, the weakening of apoptosis, and the strengthening of stemness. In the last decade, a significant number of studies focused on the application of nanotechnology in cancer treatment. Considering the anti-cancer properties of zinc, zinc oxide nanoparticles have received much attention in recent years. Some studies have indicated that zinc oxide nanoparticles can target the critical mechanisms of cancer chemo-resistance and enhance the effectiveness of chemotherapy drugs. These studies have shown that zinc oxide nanoparticles can reduce the activity of ABC transporters, increase DNA damage and apoptosis, and attenuate stemness in cancer cells, leading to enhanced chemo-sensitivity. Some other studies have also shown that zinc oxide nanoparticles in low doses can be helpful in minimizing the harmful side effects of chemotherapy drugs. In this article, after a brief overview of the mechanisms of chemo-resistance and anticancer effects of zinc, we will review all these studies in detail. |
---|---|
MeSH term(s) | Humans ; Antineoplastic Agents/adverse effects ; Zinc Oxide/therapeutic use ; Zinc Oxide/pharmacology ; Neoplasms/drug therapy ; Neoplasms/metabolism ; Nanoparticles ; Zinc/metabolism ; ATP-Binding Cassette Transporters/therapeutic use |
Chemical Substances | Antineoplastic Agents ; Zinc Oxide (SOI2LOH54Z) ; Zinc (J41CSQ7QDS) ; ATP-Binding Cassette Transporters |
Language | English |
Publishing date | 2023-08-28 |
Publishing country | United States |
Document type | Journal Article ; Review |
ZDB-ID | 445336-0 |
ISSN | 1559-0720 ; 0163-4984 |
ISSN (online) | 1559-0720 |
ISSN | 0163-4984 |
DOI | 10.1007/s12011-023-03803-z |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.B 2323: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.